A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial

被引:120
作者
Gonzalez, G
Crombet, T
Catala, M
Mirabal, V
Hernandez, JC
Gonzalez, Y
Marinello, P
Guillen, G
Lage, A
机构
[1] Ctr Mol Immunol, Havana 11600, Cuba
[2] Ctr Med Surg Res, Havana, Cuba
[3] Ctr Genet Engn & Biotechnol, Havana, Cuba
关键词
cancer vaccine; epidermal growth factor;
D O I
10.1023/A:1008261031034
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: There is evidence of a relationship between epidermal growth factor (EGF) and tumor cell proliferation, such as the overexpression of EGF receptor (EGF-R) in different human tumors, which makes this system an interesting target for cancer treatment. Up to now, passive immunotherapy with monoclonal antibodies against the EGF-R has been assayed in clinics. Our approach consists of active immunotherapy with human EGF (hu-EGF). We conducted a pilot clinical trial to define the safety, toxicity and immunogenicity of vaccination with hu-EGF coupled to a carrier protein. Patients and methods: Ten patients with histologically-proven malignant carcinomas (colon, lung, stomach and prostate) in advanced clinical stages were enrolled. Patients were immunized twice (on days 0 and 25) with hu-EGF linked to either tetanic toroid (TT, five patients) or P64k Neisseria Meningitidis recombinant protein (P64k, five patients), intradermically, using aluminium hydroxyde as adjuvant. Results. In both groups 60% of patients developed anti-EGF antibody titers without evidence of toxicity. Secondary reactions were very mild, limited to erythema and itching at the site of injection, which disappeared without medication. Conclusions: We conclude that the proposed vaccination with hu-EGF was well tolerated and that antibody titers against self EGF were developed. The results of this trial may be useful in the design of new clinical trials with higher dose immunization protocols and using more effective adjuvants.
引用
收藏
页码:431 / 435
页数:5
相关论文
共 24 条
  • [1] [Anonymous], VACCINE RES
  • [2] THE EPIDERMAL GROWTH-FACTOR RECEPTOR AS A TARGET FOR THERAPY IN BREAST-CARCINOMA
    BASELGA, J
    MENDELSOHN, J
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1994, 29 (01) : 127 - 138
  • [3] BRADY LW, 1990, FRONT RADIAT THER ON, V24, P151
  • [4] CARPENTER G, 1981, RECEPTORS RECOGNIT B, V13, P41
  • [5] THE COGNITIVE PARADIGM AND THE IMMUNOLOGICAL HOMUNCULUS
    COHEN, IR
    [J]. IMMUNOLOGY TODAY, 1992, 13 (12): : 490 - 494
  • [6] THE COGNITIVE PRINCIPLE CHALLENGES CLONAL SELECTION
    COHEN, IR
    [J]. IMMUNOLOGY TODAY, 1992, 13 (11): : 441 - 444
  • [7] COHEN S, 1962, J BIOL CHEM, V237, P1555
  • [8] EXPRESSION OF EPIDERMAL GROWTH-FACTOR RECEPTOR AND SURVIVAL IN UPPER AERODIGESTIVE TRACT CANCER
    DASSONVILLE, O
    FORMENTO, JL
    FRANCOUAL, M
    RAMAIOLI, A
    SANTINI, J
    SCHNEIDER, M
    DEMARD, F
    MILANO, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (10) : 1873 - 1878
  • [9] DIUIGI CR, 1991, J NATL CANCER I, V83, P97
  • [10] GUILLEN G, 1994, INSP MEXINCI, P834